KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables - Other
Ratios

TherapeuticsMD (TXMD) Depreciation & Amortization (IS) (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Depreciation & Amortization (IS) for 13 consecutive years, with $96000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (IS) changed 0.0% year-over-year to $96000.0, compared with a TTM value of $387000.0 through Sep 2025, down 63.0%, and an annual FY2024 reading of $509000.0, down 44.79% over the prior year.
  • Depreciation & Amortization (IS) was $96000.0 for Q3 2025 at TherapeuticsMD, roughly flat from $96000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (IS) topped out at $637000.0 in Q4 2023 and bottomed at $27000.0 in Q1 2023.
  • Average Depreciation & Amortization (IS) over 3 years is $156181.8, with a median of $100000.0 recorded in 2024.
  • Peak annual rise in Depreciation & Amortization (IS) hit 392.59% in 2024, while the deepest fall reached 84.3% in 2024.
  • Year by year, Depreciation & Amortization (IS) stood at $637000.0 in 2023, then plummeted by 84.3% to $100000.0 in 2024, then decreased by 4.0% to $96000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (IS) for TXMD at $96000.0 in Q3 2025, $96000.0 in Q2 2025, and $95000.0 in Q1 2025.